How do I install the Endo Long Acting Insulin Analog Vs Nph Basal High Risk skill?

Run npx skillmds@latest add dromlakhani/endo-long-acting-insulin-analog-vs-nph-basal-high-risk in your terminal (requires Node.js), paste this page's agent-chat prompt into Claude, Cursor, or any MCP-connected agent, or download the SKILL.md file and copy it into your agent's skills directory.

Is Endo Long Acting Insulin Analog Vs Nph Basal High Risk safe to use?

This skill has not completed SkillMD's automated safety review yet. Independent scanners report: SkillSpector: PASS, Skill Scanner: PASS. Capability flags: makes network calls. SkillMD never runs a skill's scripts for you; review the SKILL.md before installing.

Which AI agents work with Endo Long Acting Insulin Analog Vs Nph Basal High Risk?

This skill is tagged as working with Claude Code, Claude.ai, OpenAI Codex. SKILL.md is an open format, so most agents that read a skills directory can load it too.

Is Endo Long Acting Insulin Analog Vs Nph Basal High Risk free to use?

Yes. Installing skills from SkillMD is free, and the skill stays under its author's original license.

Who published Endo Long Acting Insulin Analog Vs Nph Basal High Risk?

dromlakhani (@dromlakhani) published this skill. Their other Agent Skills are listed on their SkillMD profile.

Endo Long Acting Insulin Analog Vs Nph Basal High Risk by dromlakhani

Name: Endo Long Acting Insulin Analog Vs Nph Basal High Risk
Rating: 4.2 (5 reviews)
Author: dromlakhani

Endo Long Acting Insulin Analog Vs Nph Basal High Risk

Recommends long-acting insulin analogs over human NPH insulin for basal therapy in adults and children at high hypoglycemia risk to reduce nocturnal hypoglycemia. Consider when selecting basal insulin for patients with type 1 or type 2 diabetes who have a history of severe hypoglycemia, impaired awareness of hypoglycemia, renal or hepatic impairment, or are aged over 65 years.

dromlakhani Updated Sep 8, 2026 10 repo stars

File contents

Long-Acting Insulin Analog vs Human NPH Insulin for Basal Insulin Therapy at High Hypoglycemia Risk

STEP 1 — Gather Information

Collect diabetes type, basal insulin need, hypoglycemia history (severe episodes requiring assistance, impaired awareness), renal/hepatic function (eGFR, liver enzymes), age, current basal insulin regimen and dosing frequency, and documented nocturnal hypoglycemia events. Document hypoglycemia history, renal/hepatic function, age, and current basal regimen.

STEP 2 — Rule In / Rule Out

Determine if patient meets high hypoglycemia risk criteria: history of severe hypoglycemia, impaired awareness of hypoglycemia, renal or hepatic dysfunction, or age >65 years. If high-risk criteria are met, proceed to step 3; otherwise, consider NPH based on cost/access.

STEP 3 — Classify or Stratify

Stratify by patient factors: age (pediatric vs adult), renal function (choose analogs with lower renal excretion if eGFR <30), hepatic function, and cost/access. Select appropriate long-acting analog (e.g., glargine U100/U300, detemir, degludec) based on patient factors.

STEP 4 — Decide

Prescribe chosen long-acting insulin analog once daily (or per label) and arrange follow-up within 2–4 weeks to assess hypoglycemia frequency and glycemic control.

Clinical Guardrails / Mimics / Pitfalls

Avoid analog insulins in patients with known hypersensitivity to analog excipients.
Monitor for hypoglycemia during dose titration; analogs may still cause hypoglycemia if overbasalized.
Consider cost and insurance coverage; biosimilars may reduce expense but verify interchangeability.
Do not use NPH in patients with unpredictable schedules requiring once-daily dosing preference.
Beware of mistiming doses; analogs have longer action and flexible timing but require consistent daily administration.

Concrete Clinical Example

A 70‑year‑old with type 2 diabetes, CKD stage 3 (eGFR 45), and recurrent nocturnal hypoglycemia on NPH 10 units BID switches to insulin glargine U100 10 units at bedtime; after 2 weeks, nocturnal hypoglycemia episodes decrease from 3/week to 0/week with stable fasting glucose.

Source: Management of Individuals With Diabetes at High Risk for Hypoglycemia: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2023, https://doi.org/10.1210/clinem/dgac596

---name: endo-long-acting-insulin-analog-vs-nph-basal-high-riskdescription: Recommends long-acting insulin analogs over human NPH insulin for basal therapy in adults and children at high hypoglycemia risk to reduce nocturnal hypoglycemia. Consider when selecting basal insulin for patients with type 1 or type 2 diabetes who have a history of severe hypoglycemia, impaired awareness of hypoglycemia, renal or hepatic impairment, or are aged over 65 years.---# Long-Acting Insulin Analog vs Human NPH Insulin for Basal Insulin Therapy at High Hypoglycemia Risk## STEP 1 — Gather InformationCollect diabetes type, basal insulin need, hypoglycemia history (severe episodes requiring assistance, impaired awareness), renal/hepatic function (eGFR, liver enzymes), age, current basal insulin regimen and dosing frequency, and documented nocturnal hypoglycemia events. Document hypoglycemia history, renal/hepatic function, age, and current basal regimen.## STEP 2 — Rule In / Rule OutDetermine if patient meets high hypoglycemia risk criteria: history of severe hypoglycemia, impaired awareness of hypoglycemia, renal or hepatic dysfunction, or age >65 years. If high-risk criteria are met, proceed to step 3; otherwise, consider NPH based on cost/access.## STEP 3 — Classify or StratifyStratify by patient factors: age (pediatric vs adult), renal function (choose analogs with lower renal excretion if eGFR <30), hepatic function, and cost/access. Select appropriate long-acting analog (e.g., glargine U100/U300, detemir, degludec) based on patient factors.## STEP 4 — DecidePrescribe chosen long-acting insulin analog once daily (or per label) and arrange follow-up within 2–4 weeks to assess hypoglycemia frequency and glycemic control.## Clinical Guardrails / Mimics / Pitfalls- Avoid analog insulins in patients with known hypersensitivity to analog excipients.- Monitor for hypoglycemia during dose titration; analogs may still cause hypoglycemia if overbasalized.- Consider cost and insurance coverage; biosimilars may reduce expense but verify interchangeability.- Do not use NPH in patients with unpredictable schedules requiring once-daily dosing preference.- Beware of mistiming doses; analogs have longer action and flexible timing but require consistent daily administration.## Concrete Clinical ExampleA 70‑year‑old with type 2 diabetes, CKD stage 3 (eGFR 45), and recurrent nocturnal hypoglycemia on NPH 10 units BID switches to insulin glargine U100 10 units at bedtime; after 2 weeks, nocturnal hypoglycemia episodes decrease from 3/week to 0/week with stable fasting glucose.**Source:** Management of Individuals With Diabetes at High Risk for Hypoglycemia: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2023, https://doi.org/10.1210/clinem/dgac596

Frequently asked questions